What's Happening?
The U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA® (narsoplimab-wuug), a treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy
(TA-TMA). This J-code, effective July 1, 2026, simplifies billing and reimbursement processes for patients covered by U.S. government programs and commercial payers. YARTEMLEA is the first and only approved treatment for TA-TMA, a severe complication of stem cell transplantation. The drug inhibits MASP-2, an enzyme in the lectin pathway of complement, preventing cellular injury and thrombus formation. Omeros Corporation, the developer, emphasizes the importance of this J-code in reducing administrative burdens and facilitating faster patient access.
Why It's Important?
The assignment of a permanent J-code for YARTEMLEA is significant as it provides a standardized reimbursement pathway, potentially improving access to this critical treatment for TA-TMA patients. This development is crucial given the high mortality rate associated with severe TA-TMA, which can exceed 90%. The streamlined billing process may lead to quicker treatment initiation, which is vital for patient outcomes. Additionally, the J-code supports healthcare providers by offering more predictable reimbursement, which can enhance the financial viability of administering this specialized treatment.
What's Next?
With the J-code becoming effective in mid-2026, healthcare providers and patients can expect a more efficient claims process. Omeros Corporation will continue to support access through its YARTEMLEAssist® program, which helps identify financial assistance options. The company is also awaiting a decision from the European Medicines Agency on a marketing authorization application for YARTEMLEA, which could expand its availability internationally.
